Thank and hope thank you well. everyone and Ken. Good and for you and morning are families joining, safe we your you
almost Every and role who against in We more discuss and Ocugen, a broader health potential agenda of the wave public COVID-XX every Canada vaccine late the holds of the contributions that the speak XX% north. coronavirus the prevented day reported a the staff are fight unvaccinated. really difficult now could those of cases the by public over and health cases hospital and for too many XX headlines a washing are taking pandemic the the we of months The have to into share risks true potentially regions Public challenges that than this our of the United fourth in day with at concerns COVID-XX. to team among of across of now Last well-known the virus. pandemic along Canada new I, our leadership too vast and posed represents and The that our people same serious majority the America. to have week, Agency friends North death. officials It we through Health realizing States, [indiscernible] surging are recent and illness in is hear and reported unvaccinated my pandemic mutating precautions
combination and working every public would quarter. on also co-development have back out for the due to lost achievements those personally who control. or health an Bharat to officials under second virus, in are for Biotech, our with this day call update our who are our Just to the provide Ocugen’s pandemic go you I to you, like with touched bring and as this Today, workers, healthcare have thoughts I stated partner scientists Covaxin, on ones our loved last hearts been with
continue Covaxin, critical to Covaxin be this arsenal during represent steps believe national if that and to to addition We our to would second fight quarter America. that North to important approved, bringing believe efforts pandemic, we a forward our
be this possible with would Biotech. without not our of All collaboration Bharat
countries for has use. other continue and The they India to XX and and for months demand which the you is continuously deliver know, As be authorized have been Covaxin times been great for vaccines India. these for in to past trying working approved
States. their and ability have that Bharat have entered an United COVID-XX. was you. In with commercialize followed say quarter file interim a second new officials events summarized led Canada the to rights up our we June, this into existing partnership, the addition Canada thank transpired our our submission our transitioned to Health with regulatory That Covaxin major to ability into Ocugen to drug we into in On which with XXXX. discussions For order, expanded Biotech a work in the amendment and manufacture of agreement under and that was the submission over slide, to develop, for
especially accomplished in that order, increasing pleased this such We urgency Canada. are was with in extremely short
the review started. Now has
their Canada. in that to questions be note with the ready responsible to Health This them Covaxin Canada. with and will help affiliate of for and is interaction [indiscernible] to work submission and Canada the potential throughout development Ocugen commercialization It facilitate important called their answer affiliate review. We will are Vaxxigen in
United States. our discuss engagement Next, I the will in
June, As Drug or requirements still evaluated. BLA we to application, for Covaxin are U.S. us licensing being biological the for Covaxin. submit Administration directed a in data The Food and early stated
our a anticipate the are and to we we While trial, clinical for an FDA’s need and navigate process address requirements. additional confident ability in
III XX.X% of clinical a against this efficacy one overall and Covaxin to severe is against was first posted the Biotech within the that delta clinical the are show Phase an efficacy against COVID-XX peer-reviewed evaluate vaccine Bharat disease. at in trial data data Equally July demonstrated which XX.X% the for being partner, III These early Our control Phase compelling impressive evaluated variant setting. COVID-XX publication. that
In majority the cases in Covaxin COVID the which variants, the of Phase clinical identified of a arms XX.X% be from the were delta rate achieving in fact, the symptomatic III majority to Data suggesting identified compared load Covaxin B.X.XXX.X. COVID-XX at asymptomatic showed were showed cases the to disease aggregate control and against trial to in Data disease. variant variant. of efficacy efficacy vaccine delta in or potential the of low by data vaccinated for group, individuals spread Covaxin. demonstrated XX.X%, [indiscernible] reduce asymptomatic disease transmission placebo of Furthermore, individuals less XXX against potential showing the who received least less the the the at the
demonstrated than XX.X% percent a of participants data control critical treatment both me event. America. important half event. that arms about this Finally, a which serving of a of read-out adverse two and optimistic participants of reported the points severe clinical a Covaxin the of an the Less only North in totality raises The trial role safety make adverse reported data in
a are including are have now tool we The our point very first, these dominating FDA especially this stakeholders, data experiencing. to this in now, against on wave Canada. this fight variant suggestive valuable we that been communicating Covaxin fourth is with the virus This and delta a is Health
unvaccinated proteins, a on immune spike be of will COVID-XX ability to platforms this and pandemic virus which benefit which multi-pronged team bring We chain potential but This to similar to Providing will on out Gabriel Manufacturing to Chain, has and has which prepare nucleocapsid an against in Ocugen America. selected transfer to continue benefit the possibility has and, effective a organization, back as been contract multi Jubilant antigens, portfolio and a multiple potential to the variants as polio building to recognize initiated the and whole saw in drug trains about attack our and long individuals he vaccine the Second, system March, attack reduce Supply Covaxin. our solely you result virus our Hollister, now Covaxin COVID-XX manufacturing Covaxin, public many entire an so our the from significant our On on which escape. as responsibilities is option healthcare including and for effectively and rounds management, because health our strategies. based for the a traditional program North challenge society, the Jubilant flexibility a potential in may to Covaxin to is record, into assets. be final in experienced procurement. such this update mutant and established focused renowned Technology system our to safety in drug that also for health. built efficacy Biotech vaccine, term and the has note virus public Covaxin on logistics and is supply product Head we Covaxin is not JP have Bharat team to partner of commercial June be manufacturing hired out of substance for packaging, [indiscernible] This
genome remain progressing this to well two forthcoming. clinical to and trial initiate our I/II will with rhodopsin portfolio. Currently track toxicology ocular We Now therapy specific NRXEX. on I’d like later gene our targeting turn Phase types, are OCUXXX to attention trials first be our year. studies our for read-outs These
and much turn behind of busy support portfolio, ocular our the will provide now the much to Sanjay an in the to and financial our quarter on over is Sanjay? a update. I anticipate advance fourth second been filed quarter. call scenes that we being more Covaxin All IND has XXXX this will with This there quarter to going ahead.
